Quoin Pharmaceuticals To Announce Corporate Update And Fourth Quarter And Full-Year 2025 Financial Results On Thursday, March 26, 2026

(MENAFN- GlobeNewsWire - Nasdaq) ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025.

About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: or LinkedIn for updates.

For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
...

Investor Relations
PCG Advisory
Jeff Ramson
...
(646) 863-6341

MENAFN19032026004107003653ID1110883143